Category Archives: Business and Investments

Latest From Business and Investments

Panelists ponder when the window will open

Panelists in this afternoon’s business roundtable “Window Shopping – The Buyer’s Perspective on Today’s IPO Candidates” contemplated what it’s going to take to return to a vibrant IPO market. “What we need is public market examples of IPOs that are successful,” said Ashley Dombkowski, PhD, a managing director at MPM Capital. Daniel Lyons, PhD, CFA, an equity research analyst at Janus Capital added that having a lack of opportunities can make a company stand out Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Healthcare reform: sustaining biotech innovation in a new world

The Eighth Annual BIO Investor Forum kicked off today with a plenary session on health care reform with expert panelists who are entrenched in the day-to-day debate of the most comprehensive changes ever proposed for the U.S. health care system. Panelists agreed that it’s been a long and complicated debate and the end of year deadline is ambitious yet within the realm of possibility. Michelle Easton, a partner at Tarplin, Downs and Young, LLC, asserted that Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Guest blogger post: The Lure of Translational Research

As a breast cancer advocate, I am seduced by the lure of translational research and the promises of personalized medicine that will make the one size fits all approach to cancer treatment obsolete and possibly reduce over-treatment, toxicity, and treatment errors. I will be attending the BIO Technology Transfer Symposium and BIO Investor Forum next week and will look forward to hearing insights from biotech industry leaders. The Tech Transfer Symposium will address opportunities and Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

The Burrill Report Interview with Jim Greenwood

The Burrill Report’s Daniel Levine spoke with Jim Greenwood, president and CEO of BIO, about the upcoming Eighth Annual BIO Investor Forum’s opening plenary session on healthcare reform. Greenwood will be moderating the session, “Healthcare Reform: Sustaining Biotech Innovation in a New World.” Listen to the podcast.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Development continues for osteoporosis drug

Osteologix, Inc. (OLGX.OB) will continue the clinical development for its osteoporosis drug, NB S101 (strontium malonate), in the U.S. and worldwide. Additionally, the company wants to recognize World Osteoporosis Day’s significance and make more people aware of its research dedicated to improving the lives of people with osteoporosis. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,